ALFA Finder India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold Telegram alerts alfafinder.com →
Saturday, 14 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Earnings Call

Sheel Biotech Earnings Call: Key Takeaways

Sheel Biotech is pivoting into the high-margin blueberry market, targeting ₹110 Cr+ revenue for FY26 using its established tissue culture and greenhouse infrastructure.

Guidance and delivery
Management target Revenue 10.0% FY26
Highlights
MarginsBlueberry commands 6x strawberry price; shifting to premium 18-25mm grades.
Order book₹50.11 Cr across 20 orders; NAFED largest contract (₹12.95 Cr).
Demand visibilityStrong; 10x growth in imports since 2020.
Management confidenceHigh; leveraging 30+ years of tissue culture DNA.

Growth

Projected FY26 revenue exceeds ₹110 Cr, up from ₹100 Cr+ in 2024. Indian blueberry demand is growing at 18% CAGR.

Outlook

Expanding blueberry commercial footprint; current order inflow of ₹50.11 Cr across 20 contracts for FY26.

Risks

High-capital intensive greenhouse setup and dependence on specific climate zones for blueberry varieties.

Source

Earnings Call filed with NSE, NSE: SHEEL. Summary written with AI assistance from the document.

Read the document ↗

Sheel Biotech Ltd: key numbers

Share price
₹61.00
Market cap
₹124.2 Cr
Revenue (annual)
₹110.0 Cr
Net profit (annual)
₹11.76 Cr
P/E (TTM)
10.6×Sector 46.1×
Promoter holding
72.31%
FII holding
0.00%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Sheel Biotech Ltd

All →